Cognition Therapeutics, Inc. (CGTX) vs ProMIS Neurosciences, Inc. (PMN)

A side-by-side comparison of Cognition Therapeutics, Inc. and ProMIS Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Cognition Therapeutics, Inc. logo
CGTX
Cognition Therapeutics, Inc.
$85M
$0.95HealthcareDelayed quote: Oct 6, 2026, 11:59 AM EDT
ProMIS Neurosciences, Inc. logo
PMN
ProMIS Neurosciences, Inc.
$85M
$9.43HealthcareDelayed quote: Oct 6, 2026, 11:59 AM EDT

Total return — CGTX vs PMN

growth of $100 · dividends reinvested · last 5y
CGTX -92.7% (-40.7%/yr)PMN -95.8% (-47.0%/yr)CGTX compounded faster over this window
020406080100Start $10020222023202420252026$7$4
CGTX PMN

CGTX vs PMN: by the numbers

  • •CGTX is the larger company ($85M vs $85M market cap).

Metrics side by side

Valuation

MetricCGTXPMN
P/B ratio2.571.71

Profitability

MetricCGTXPMN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-50.80%-85.48%
ROIC-109.43%-87.79%

Growth (annualized)

MetricCGTXPMN
Total return CAGR (5Y)N/A-47.05%

Go deeper

Full CGTX analysisFull PMN analysisInteractive comparison tool

Dig into the metrics

Cognition Therapeutics ROEProMIS Neurosciences ROECognition Therapeutics operating marginProMIS Neurosciences operating marginCognition Therapeutics revenue growthProMIS Neurosciences revenue growthCognition Therapeutics free cash flowProMIS Neurosciences free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.